SCHEMBL7785774

SCHEMBL7785774

CCO/C=C(\F)C(=O)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.42
GLO1 Q04760 1/20 0.42
ALDH1A1 P00352 4/20 0.39
CYP2D6 P10635 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 3/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 5/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
CYP2C9 P11712 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
TSHR P16473 1/20 0.36
ALOX15 P16050 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
SOAT1 P35610 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21974585 1.00 NPSR1 (0.42) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL7785776 1.00 NPSR1 (0.42) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL4297861 0.83 NPSR1 (0.42) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL3439196 0.79
SCHEMBL265509 0.79
SCHEMBL222772 0.77 GLO1 (0.50) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL19447665 0.77 GLO1 (0.50) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL7786273 0.77
SCHEMBL7786274 0.77
SCHEMBL322511 0.77 GLO1 (0.50) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410179-B2 Modulators of TNF alpha activity and uses thereof RAYTHERA, INC. (US) 2025-09-09 US disclosed
US-20250263418-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF RAYTHERA, INC. 2025-08-21 US disclosed
CN-119630670-A Modulators of TNFalpha activity and uses thereof 瑞雷拉公司 2025-03-14 CN disclosed
US-20250066375-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF RAYTHERA, INC. 2025-02-27 US disclosed
WO-2025038927-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF RAYTHERA, INC. (US) 2025-02-20 WO disclosed
EP-0971919-B1 PROCESS FOR PREPARATION OF 4H-4-OXO-QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES ABBOTT LAB (US) 2001-10-31 EP disclosed
EP-0971919-A1 PROCESS FOR PREPARATION OF 4H-4-OXO-QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES Abbott Laboratories (US) 2000-01-19 EP disclosed
WO-1998038191-A1 PROCESS FOR PREPARATION OF 4H-4-OXO-QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES ABBOTT LABORATORIES (US) 1998-09-03 WO disclosed
US-5693813-A Process for preparation of 4H-4-oxo-quinolizine-3-carboxylic acid ABBOTT LABORATORIES (US) 1997-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066375-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF TNF, TNFRSF1A, TNFRSF9 NPSR1 3259/4885GLO1 2332/4885ALDH1A1 2619/4885
US-12410179-B2 Modulators of TNF alpha activity and uses thereof TNF, TNFRSF1A, TNFRSF9 NPSR1 3259/4885GLO1 2332/4885ALDH1A1 2619/4885
US-20250263418-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF TNF, TNFRSF1A, TNFRSF9 NPSR1 3259/4885GLO1 2332/4885ALDH1A1 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.